FX.co ★ GSK Reaches $2.2 Bln Settlement Over Zantac Liability Cases

GSK plc announced that it has reached agreements with legal representatives from 10 firms, which cover approximately 93% (or roughly 80,000) of the Zantac (ranitidine) product liability lawsuits currently pending in U.S. state courts.

Under the terms of these settlements, GSK will allocate up to $2.2 billion to settle all U.S. state court product liability cases managed by the participating law firms that meet certain eligibility and participation criteria.

The involved plaintiff firms are unanimously advising their clients to agree to the settlement's terms, which are confidential and set to be fully enacted by mid-2025.

Moreover, GSK has provisionally agreed to disburse $70 million to resolve a Zantac qui tam lawsuit previously filed by Valisure, an agreement pending Department of Justice approval.

GSK has not admitted any fault in either the State Courts Settlement or the Qui Tam Settlement agreements. The company asserts that these settlements serve the long-term best interests of GSK and its shareholders by mitigating financial uncertainty, risk, and distractions associated with ongoing legal proceedings.

GSK plans to report an additional expenditure of £1.8 billion (or $2.3 billion) in its third-quarter 2024 financial results. This charge accounts for the State Courts Settlement, the Qui Tam Settlement, and the outstanding 7% of unresolved state court product liability cases. This expense is expected to be partially offset by anticipated reductions in future legal costs.

These settlement costs will be covered using existing company resources, according to GSK.